L-glucose, a mirror isomer of D-glucose, is usually considered unusable by living organisms. However, in 2010, we discovered that malignant tumor cells specifically take up L-glucose (patented internationally). We have since worked with physicians and researchers to develop cancer-targeting drugs and diagnostics using L-glucose. Our goal is to bring a cure to patients with intractable cancers.
We provide contract analysis services utilizing mass spectrometry imaging. This technology enables visualization of “where, what components, and how much.” It is applicable to pharmacokinetic studies, cosmetic development, and various other fields.
A startup that synthesizes long, complex DNA using proprietary technology, enabling the flexible design of diverse gene combinations. It also provides comprehensive support from development to manufacturing processes for viral vectors and mRNA required for gene therapy.
A startup overcoming challenges in exosome purification with proprietary high-purity, high-yield technology, offering end-to-end support from research to manufacturing. It accelerates practical applications in drug discovery, contributing to a new foundation for pharmaceutical development and driving medical innovation.
An Osaka University-spinoff startup enabling high-precision testing in a short time using proprietary immunoassay technology. Aiming to realize a society where anyone can easily access medical-grade testing.
